- Case report
- Open Access
A rare case of chronic myeloid leukemia with secondary chromosomal changes including partial trisomy 17q21 to 17qter and partial monosomy of 16p13.3
© Al Achkar et al; licensee BioMed Central Ltd. 2010
Received: 28 January 2010
Accepted: 16 March 2010
Published: 16 March 2010
The so-called Philadelphia (Ph) chromosome is present in almost all cases with chronic myeloid leukemia (CML). Around 5-10% of these patients show complex translocations involving other chromosomes in addition to and/or besides chromosomes 9 and 22. As nowadays most CML cases are treated with Imatinib, variant rearrangements have in general no specific prognostic significance, though events of therapy resistance remain to be studied.
Here we report a Ph chromosome positive patient with hematological typical chronic phase CML. Untypically, an unbalanced complex rearrangement involving chromosomes 16 and 17 leading to a deletion of 16pter and partial trisomy of 17q21 to 17qter, was identified besides a trisomy 8 and an additional Ph chromosome in a part of malignant cells.
Here a novel and cytogenetically unique case of a Ph chromosome positive CML clinically in chronic phase is reported, having complex secondary chromosomal aberrations. Thus, CML patients with complex chromosomal changes are nonetheless treatable by Imatinib.
Chronic myeloid leukemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of the Philadelphia (Ph) chromosome in more than 90% of patients. The Ph chromosome is a product of the reciprocal translocation t(9;22)(q34;q11), which transposes the 3' portion of the ABL oncogene from 9q34 to the 5' portion of the BCR gene on 22q11.2. The crucial pathogenetic consequence of this translocation is the creation of a chimeric BCR/ABL gene on the derivative chromosome 22 . The expression of the BCR/ABL chimeric protein with an increased tyrosine kinase activity plays an essential role in the pathogenesis of CML .
The progression of CML from chronic phase (CP) to blast crisis (BC) is frequently associated with nonrandom secondary chromosomal aberrations such as +8, i(17q), +19 and an extra Ph chromosome . Imatinib mesylate (Glivec, formerly STI571) was designed specifically to inhibit the tyrosine kinase activity of the BCR/ABL protein and other tyrosine kinases such as cABL, c-KIT and PDGF (platelet-derived growth factor receptor). By binding to an active site of the tyrosine kinase, Glivec switches off downstream signaling, cells stop proliferating and apoptosis ensues . Many studies have shown a high efficiency of Imatinib therapy to achieve a complete or major cytogenetic response, i.e. a reduction to 0-34% Ph-positive cells. This positive effect may be attained in cases with a simple t(9;22), in such with complex translocations resulting in a BCR/ABL fusion gene, as well as in cases with cytogenetic clonal evolution [5, 6].
Herein we report a rare case of a Ph chromosome positive CML with a derivative chromosome 16 leading to a partial trisomy 17q21 to 17qter and partial deletion of 16pter, which was nonetheless successfully treatable by Imatinib.
A 30-year old male was diagnosed to suffer from CML in CP after a blood cell count was initiated in June 2009 due to splenomegaly and severe loss of weight. The patient was treated with Imatinib mesylate at a 400 mg/day for overall 12 months and previous relevant symptoms disappeared. Hematologic parameters were as follows: hemoglobin 129 g/l; platelets count was 103 × 109/l; and white blood cells (WBC), 5 × 109/l with 57.2% neutrophils, 36.3% lymphocytes, 4.8% monocytes, 1.3% eosinophiles and 0.4% basophiles.
In a case of a CP Ph chromosome positive CML additional chromosomal changes were detected. Apart from a trisomy 8 and an additional derivative chromosome 22 two additional chromosomal alterations were present: an intrachromosomal rearrangement involving 16q22, 16p11.3 and an interchromosomal one with breakpoints in 16q22 and 17q21. To our knowledge, this translocation has been never observed in CML before .
In 5-10% Ph chromosome CML cases have complex translocations in addition to those and/or besides chromosomes 9 and 22 . At present it appears that in such rearrangements any other chromosome may be involved. However, it has been suggested that distribution of chromosomes and breakpoints is non-random with the chromosomal bands most susceptible to breakage being 1p36, 3p21, 5q31, 6p21, 9q22, 10q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12 and 22q13 , showing one match with the present case, i.e. 17q21.
Additionally, the two breakpoints in chromosome 16 have previously been reported to be associated with acute nonlymphocytic leukemia (ANLL) type M4 . 16q22 is frequently found in the ANLL typical inversion (16)(p13q22) and the related interchromosomal translocation (16;16)(p13;q22). These chromosome 16 rearrangements resulted in the disruption of the myosin heavy chain (MYH11) gene mapping to chromosome 16p13.13 to 16p13.12 . MYH11 encodes the smooth-muscle myosin heavy chain and belongs to the family of conventional myosins. The well-characterized biological function of myosins is their ability to use the energy of ATP hydrolysis to move actin filaments and produce muscle force. Recently, myosins have been implicated in a variety of other intra-cellular functions, including cell migration, adhesion, control of cell shape, and membrane traffic but are implicated also in a variety of other cellular functions, many of which are relevant for cancer formation . Unfortunately, in the present case no material was available to test if MYH11 was involved in the rearrangement.
During CML progression trisomy of chromosomes 8 and a second Ph chromosome are frequent anomalies in CML . Also, another leukemogenic effect of the der(16) may be due to increase copy number of the 17q21 to 17qter region. Morerio et al.  have reported that trisomies for this region represent a negative prognostic indicator in myeloid neoplasia. Also an isochromosome 17q is a well-known progression step in CML.
In conclusion, here we reported a novel and cytogenetically unique case of a Ph chromosome positive CML in CP. Especially the latter fact being still a CML in CP and not in BC when having such complex secondary chromosomal aberrations is intriguing. We suggest that the reported patient had nonetheless such a good response to Imatinib as irrespective of complex chromosomal changes he was treated 'just in time' before further mutations appeared leading to BC.
Materials and methods
Chromosome analysis using GTG-banding was done according to standard procedures . 20 metaphases analyzed from unstimulated bone marrow culture were analyzed. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature .
Fluorescence in situ hybridization (FISH) using LSI BCR/ABL dual color dual fusion translocation probe (Abbott molecular/Vysis, USA) and subtelomeric probe for 16pter (Abbott molecular/Vysis, USA) were applied according to manufacturer's instructions together with a whole chromosome painting (WCP) probe for chromosome 17 . Array-proven multicolor banding probe (aMCB) sets based on microdissection derived region-specific libraries for chromosome 16 and 17 were applied as described  20 metaphase spreads were analyzed, each using a fluorescence microscope (AxioImager.Z1 mot, Zeiss) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes and the counterstain DAPI (Diaminophenylindol). Image capturing and processing were carried out using an ISIS imaging system (MetaSystems, Altlussheim, Germany) for the evaluation aMCB.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We thank Dr. I. Othman, the Director General of Atomic Energy Commission of SYRIA (AECS) and Dr. N. Mirali, Head of Molecular Biology and Biotechnology Department for their support. This work was supported by the AECS, in parts by the Stefan-Morsch-Stiftung, Monika-Kutzner-Stiftung and the DAAD (D/07/09624).
- La Starza R, Testoni N, Lafage-Pochitaloff M, Ruggeri D, Ottaviani E, Perla G, Martelli MF, Marynen P, Mecucci C: Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia. Haematologica 2002, 87: 143–147.PubMedGoogle Scholar
- Lugo T, Pendergast A, Müller A, Witte O: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247: 1079–1082. 10.1126/science.2408149PubMedView ArticleGoogle Scholar
- Sandberg AA: The chromosomes in Human Cancer and leukemia. 2nd edition. Elsevier Science, New York; 1990:151–172.Google Scholar
- Griffen J: The biology of signal transduction The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001, 28: 3–8.View ArticleGoogle Scholar
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E, International STI571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346: 645–652. 10.1056/NEJMoa011573PubMedView ArticleGoogle Scholar
- Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM: Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003, 101: 3794–3800. 10.1182/blood-2002-09-2790PubMedView ArticleGoogle Scholar
- Mitelman F, Johansson B, Mertens F (Eds): Mitelman Database of Chromosome Aberrations in Cancer (2009) In [http://cgap.nci.nih.gov/Chromosomes/Mitelman]Google Scholar
- Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002, 107: 76–94. 10.1159/000046636PubMedView ArticleGoogle Scholar
- Liu P, Tarle SA, Hajra A, Claxton DF, Marlton P, Freedman M, Siciliano MJ, Collins FS: Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993, 261: 1041–1044. 10.1126/science.8351518PubMedView ArticleGoogle Scholar
- Deng Z, Liu P, Marlton P, Claxton DF, Lane S, Callen DF, Collins FS, Siciliano MJ: Smooth muscle myosin heavy chain locus (MYH11) maps to 16p13.13-p13.12 and establishes a new region of conserved synteny between human 16p and mouse 16. Genomics 1993, 18: 156–159. 10.1006/geno.1993.1443PubMedView ArticleGoogle Scholar
- Krendel M, Mooseker MS: Myosins: tails (and heads) of functional diversity. Physiology (Bethesda) 2005, 20: 239–251.View ArticleGoogle Scholar
- Morerio C, Russo I, Rosanda C, Rapella A, Leszl A, Basso G, Maserati E, Pasquali F, Panarello C: 17q21-qter trisomy is an indicator of poor prognosis in acute myelogenous leukaemia. Cancer Genet Cytogenet 2001, 124: 12–15. 10.1016/S0165-4608(99)00229-0PubMedView ArticleGoogle Scholar
- Claussen U, Michel S, Mühlig P, Westermann M, Grummt UW, Kromeyer-Hauschild K, Liehr T: Demystifying chromosome preparation and the implications for the concept of chromosome condensation during mitosis. Cytogenet Genome Res 2002, 98: 136–146. 10.1159/000069817PubMedView ArticleGoogle Scholar
- Shaffer L, Slovak M, Cambell L, (eds): ISCN (2009): An International System for Human Cytogenetic Nomenclature. S. Karger, Basel 2009.Google Scholar
- Liehr T, Starke H, Weise A, Lehrer H, Claussen U: Multicolor FISH probe sets and their applications. Histol Histopathol 2004, 19: 229–237.PubMedGoogle Scholar
- Liehr T, Heller A, Starke H, Rubtsov N, Trifonov V, Mrasek K, Weise A, Kuechler A, Claussen U: Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med 2002, 9: 335–339.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.